ClinicalTrials.gg
RecruitingNCT05627908PseAnUpdated Apr 16, 2026

The PseAn Study - Study Protocol

An observational study in Abdominal Trauma and Follow-up in Abdominal Trauma, sponsored by Niguarda Hospital. Recruiting at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-16.

Sponsored by Niguarda Hospital · Observational

From the registry’s dates

  • Started Oct 2022; still recruiting 4 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
385
Ages
18 Years and older
Sex
All
01

Study summary

The researchers aim to study the role of contrast ultrasound in detecting post-traumatic splenic, hepatic, and renal PAs compared with the gold standard of CT with intravenous contrast at different follow-up time points, and whether it can replace CT scan in the follow-up of solid organ injuries

Read the detailed description

Adult patients (18 years old and above) with proven blunt or penetrating splenic and/or liver and/or renal trauma as shown by a CT scan and classified according to the American Injury Scale American Association for Surgery (AAST) Organ Injury Scale (OIS) with OIS III and above will undergo a follow-up with both a CEUS and CT scan to detect post-traumatic parenchymal pseudoaneurysm within two to five days from injury. Follow-up over five days post-admission will be included if they were performed within the same hospitalization

02

Conditions studied

  • Abdominal Trauma
  • Follow-up in Abdominal Trauma

Keywords

  • trauma
  • CT scan
  • CEUS
  • follow up
  • abdominal pseudoaneurism
03

In context

Abdominal Injuries

60 studies on the registry are indexed under Abdominal Injuries; 19 are open to participants now.

This study's planned enrollment of 385 is above the median of 200 across 30 observational studies indexed under Abdominal Injuries.

Browse Abdominal Injuries studies →

Lead sponsor

Niguarda Hospital is the lead sponsor of 68 studies on the registry; 29 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

adult patients (18 years old and above) with proven blunt or penetrating splenic and/or liver and/or renal trauma as shown by a CT scan and classified according to the American Injury Scale American Association for Surgery (AAST) Organ Injury Scale (OIS) will be included

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • adult patients (18 years old and above) with proven blunt or penetrating splenic and/or liver and/or renal trauma as shown by a CT scan and classified according to the American Injury Scale American Association for Surgery (AAST) Organ Injury Scale (OIS) will be included

Exclusion criteria

Exclusion Criteria:

  • minor to 18 years old
05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
385 participants (estimated)
Patient registry
No

Groups and cohorts

  • abdominal trauma

    CEUS in detecting post-traumatic splenic, hepatic, and renal PAs

    Other: Contrast-enhanced ultrasound

Interventions

  • OtherContrast-enhanced ultrasound

    Patients data monitoring with medium- and high-grade trauma to the liver, spleen, and kidney

06

What researchers measure

Primary outcomes

  1. Pseudoaneursim (PA)

    In each centre, the coordinator will collect epidemiological, clinical, and surgical data on a case report form (CRF) that will be completed through a questionnaire by accessing a protected database. The protocol for data collection is shown in appendix 1 (attached). The link for accessing the completion of the CRF will be sent by email, to the Main Lead of each participating centre. The main outcome will be the number of post-traumatic Pseudoaneurysms identified with CT scan and CEUS. The sample size for unknown populations has been derived according to the formula N= Z2 x p (1-p)/ e2, setting standard deviation (SD) at 50%, confidence interval at 95%, and Z-score at 1.65. The minimum sample size was 385 patients with a sampling error of ± 5%.

    Time frame: up to 5 days post patients admission

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2022 (actual). Primary completion is estimated for Oct 2026, 48 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 17, 2022
First posted
Nov 28, 2022
StartActual
Oct 1, 2022
Primary completionEst.
Oct 31, 2026
CompletionEst.
Dec 31, 2027
Last update
Apr 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05627908
Lead sponsor
Niguarda Hospital
Responsible party
Sponsor
First posted
Nov 28, 2022
Start date
Oct 1, 2022
Primary completion
Oct 31, 2026 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Apr 16, 2026

Study contacts

Francesco Virdis, MD
Contact
francesco.virdis@ospedaleniguarda.it
+393519639712

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion